Disease · MONDO_0004648
Trials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 17 of 17
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00889603 | Non-Interventional Study With Aricept® Evess | 370 | 2011-03-31 | Alzheimer's Disease, Vascular Dementia | DONEPEZIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00174382 | Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia | Phase 3 | 149 | 2009-06-12 | Dementia, Vascular, Dementia, Mixed | DONEPEZIL | Its record names the disease | ClinicalTrials.gov |
| NCT04219774 | NeuroCognition After Carotid Recanalization | Phase 2 | 25 | 2025-05-09 | Cognition Disorder, Stroke, Occlusion Carotid | ASPIRIN, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov |
| NCT00814502 | Zolpidem CR and Hospitalized Patients With Dementia | Not applicable | 20 | 2017-05-22 | Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation | ZOLPIDEM | Its record names the disease | ClinicalTrials.gov |
| NCT00099216 | Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia | Phase 3 | 708 | Vascular Dementia | RIVASTIGMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00261573 | A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia | Phase 3 | 593 | Alzheimer Disease, Vascular Dementia | GALANTAMINE HYDROBROMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02453932 | Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia | Phase 3 | 543 | Vascular Dementia | DONEPEZIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00130338 | Rivastigmine Capsules in Patients With Probable Vascular Dementia | Phase 3 | 521 | Vascular Dementia | RIVASTIGMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00035191 | A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia | Phase 3 | 254 | Dementia, Vascular | GALANTAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01475578 | Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) | Phase 2 | 240 | Vascular Dementia | ERGOLOID MESYLATES | Its record names the disease | ClinicalTrials.gov | |
| NCT04966429 | Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment | Phase 2 | 150 | Post Stroke Cognitive Impairment | MARAVIROC | Its record names the disease | ClinicalTrials.gov | |
| NCT05262257 | Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus. | Early phase 1 | 120 | Type2 Diabetes | DAPAGLIFLOZIN, METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05173896 | Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial | Phase 2 | 100 | Cerebral Small Vessel Diseases, Stroke, Ischemic | TADALAFIL | Its record names the disease | ClinicalTrials.gov | |
| NCT03451760 | Feru-guard for Behavioral Symptoms in Dementia | Phase 2 | 70 | Behavioral and Psychiatric Symptoms of Dementia | FERULATE | Its record names the disease | ClinicalTrials.gov | |
| NCT05336175 | Biomarker Study: Heart Failure Patients at Risk | Phase 1/2 | 40 | Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV | SODIUM CHLORIDE, TALFIRASTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06718686 | Rifaximin SSD in Dementia Trial | Phase 1/2 | 20 | Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease | RIFAXIMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00457769 | Aricept to Improve Functional Tasks in Vascular Dementia | Phase 1 | 18 | Stroke, Vascular Dementia, Memory Deficits | DONEPEZIL | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004648/trials